Track topics on Twitter Track topics that are important to you
Here are the most relevant search results for "Daiichi Pharmaceutical" found in our extensive news archives from over 250 global news sources.
In addition to our news stories we have dozens of PubMed Articles about Daiichi Pharmaceutical for you to read. Along with our medical data and news we also list Daiichi Pharmaceutical Clinical Trials, which are updated daily. BioPortfolio also has a large database of Daiichi Pharmaceutical Companies for you to search.
Daiichi Sankyo is set to restructure its wholly-owned Kitasato Daiichi Sankyo Vaccine subsidiary into a specialised manufacturing division to enhance...Read More... The post Daiichi Sankyo to restructure vaccines subsidiary appeared first on Pharmaceutical Technology.
Daiichi Sankyo has transferred 41 of its long-listed products to Alfresa Pharma. The transaction also includes products manufactured by Daiichi...Read More... The post Deals this week: Daiichi Sankyo, MannKind, Dova Pharmaceuticals appeared first on Pharmaceutical Technology.
Daiichi Sankyo has formed a new consortium focused on research and discovery of medicines over a period of five years...Read More... The post Daiichi Sankyo to develop new inflammatory disease drugs appeared first on Pharmaceutical Technology.
Daiichi Sankyo has announced plans to split and transfer its inventories to Alfresa Pharma, along with Japanese manufacturing and sales...Read More... The post Daiichi Sankyo transfers 41 products to Alfresa Pharma appeared first on Pharmaceutical Technology.
Twist Bioscience has completed a private placement of shares to raise $50m. The company plans to use part of the...Read More... The post Deals this week: Twist Bioscience, Kangmei Pharmaceutical, Daiichi Sankyo appeared first on Pharmaceutical Technology.
Daiichi Sankyo’s pivotal data presentation at this year’s European Hematology Association (EHA) annual meeting showed that its FLT3 inhibitor quizartinib...Read More... The post EHA 2018: pivotal Phase III data for Daiichi Sankyo’s quizartinib appeared first on Pharmaceutical Technology.
Daiichi Sankyo has secured orphan drug designation from the Japan Ministry of Health, Labour and Welfare (MHLW) for its axicabtagene...Read More... The post Daiichi Sankyo’s lymphoma therapy gets orphan drug status in Japan appeared first on Pharmaceutical Technology.
TOKYO and MUNICH and BASKING RIDGE, N.J., Oct. 21, 2018 /PRNewswire/ -- Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced that updated phase 1 safety Read more...
Mylan has formed a partnership with Atomo Diagnostics to expand access to HIV self-testing products in developing and under-developed countries....Read More... The post Deals this week: Mylan, Daiichi Sankyo, Takeda appeared first on Pharmaceutical Technology.
TOKYO, BERLIN, BASKING RIDGE, NJ / ACCESSWIRE / July 30, 2018 / Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and Glycotope GmbH (hereafter, Glycotope) have entered into an exclusive ...
Daiichi Sankyo's quizartinib, being developed to treat patients with relapsed or refractory acute myeloid leukemia with an FL -More-
Daiichi Sankyo has entered into a clinical trial collaboration agreement with a subsidiary of MSD to evaluate a potential new combination therapy for breast or lung cancers.
Japanese companies Daiichi Sankyo and The Chemo-Sero-Therapeutic Research Institute – known as Kaketsuken…
Tokyo, Munich and Basking Ridge, NJ – (August 1, 2018) – Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to quizartinib, an...
Daiichi Sankyo's quizartinib, a drug being tested in a Phase III trial as a treatment for patients with relapsed or refractor -More-
Daiichi Sankyo announced it has entered into a clinical trial collaboration agreement with Merck & Co. to evaluate an investigational lung cancer treatment.
Tokyo, Basking Ridge, NJ, and Munich – (June 4, 2018) – Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that the phase 3 ENLIVEN study showed a statistically significant 39 percent overall response rate (ORR) at week...
Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Daiichi DMD trial misses primary efficacy endpoint .An early-phase trial of Daiichi Sankyo’s Duchenne muscular dystrophy (DMD) drug has failed to show clear evidence of efficacy. But, buoyed … Continue reading → Cet article #news #biotech Daiichi DMD trial misses...
The deal combines Daiichi Sankyo’s ADC technology with Glycotope’s investigational tumor-associated TA-MUC1 antibody gatipotuzumab (formerly PankoMab-GEX), building on a previous 2017 option agreement. Under the terms of the The post Daiichi Sankyo signs licensing deal with Glycotope for Gatipotuzumab ADC appeared first on Pharma Business review.
Ken Truitt has been appointed chief medical officer of immune drug developer ImmusanT. Truitt comes to the Cambridge, MA, biotech from Daiichi Sankyo, where he was senior vice president for internal medicine therapies. Before joining Daiichi Sankyo, Truitt was director of clinical research in the pulmonary-immunology division of Merck (NYSE: MRK). Last fall, ImmusanT raised […]
Daiichi Sankyo and a subsidiary of Merck, known as MSD outside North America, agreed to work together to develop the former's -More-
AstraZeneca and Daiichi Sankyo introduced in Japan its proton pump inhibitor Nexium, or esomeprazole magnesium hydrate, in 10 -More-
Tokyo, Munich, and Basking Ridge, NJ – (May 8, 2018) – Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announces that the pivotal QuANTUM-R phase 3 study of single agent quizartinib met its primary endpoint of significantly...
Canada’s Zymeworks and Japan’s Daiichi Sankyo have entered into a new license agreement, expanding…
Daiichi Sankyo Company has signed a clinical trial collaboration agreement with a Merck subsidiary to conduct a Phase lb trial...Read More... The post Daiichi Sankyo forms collaboration for Phase lb trial of DS-8201 appeared first on Drug Development Technology.